Publicacións nas que colabora con Cristina Alenda González (17)

2024

  1. Prediction of metachronous advanced colorectal neoplasia by KRAS mutation in polyps

    United European Gastroenterology Journal

2020

  1. Clinical and Pathological Characterization of Lynch-Like Syndrome

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 2, pp. 368-374.e1

  2. Risk of cancer in family members of patients with lynch-like syndrome

    Cancers, Vol. 12, Núm. 8, pp. 1-12

2017

  1. Increased Risk of Colorectal Cancer in Patients With Multiple Serrated Polyps and Their First-Degree Relatives

    Gastroenterology, Vol. 153, Núm. 1, pp. 106-112.e2

2016

  1. Endoscopic surveillance in patients with multiple (10-100) colorectal polyps

    Endoscopy, Vol. 48, Núm. 1, pp. 56-61

2014

  1. High incidence of large deletions in the PMS2 gene in Spanish Lynch syndrome families

    Clinical Genetics, Vol. 85, Núm. 6, pp. 583-588

  2. Prevalence and characteristics of mutyh-associated polyposis in patients with multiple adenomatous and serrated polyps

    Clinical Cancer Research, Vol. 20, Núm. 5, pp. 1158-1168

2013

  1. Clinical subtypes and molecular characteristics of serrated polyposis syndrome

    Clinical Gastroenterology and Hepatology, Vol. 11, Núm. 6, pp. 705-711

  2. Risk of cancer in cases of suspected lynch syndrome without germline mutation

    Gastroenterology, Vol. 144, Núm. 5

2012

  1. COGENT (COlorectal cancer GENeTics) revisited

    Mutagenesis, Vol. 27, Núm. 2, pp. 143-151

2011

  1. 5-fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer

    Gastroenterology, Vol. 140, Núm. 4, pp. 1174-1181

2010

  1. Colorectal cancer prognosis twenty years later

    World Journal of Gastroenterology, Vol. 16, Núm. 7, pp. 862-867

  2. Susceptibility genetic variants associated with colorectal cancer risk correlate with cancer phenotype

    Gastroenterology, Vol. 139, Núm. 3

2009

  1. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status

    European Journal of Cancer, Vol. 45, Núm. 3, pp. 365-373

2008

  1. Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients

    Journal of Medical Genetics, Vol. 45, Núm. 9, pp. 557-563

2006

  1. Clinical performance of original and revised Bethesda guidelines for the identification of MSH2/MLH1 gene carriers in patients with newly diagnosed colorectal cancer: Proposal of a new and simpler set of recommendations

    American Journal of Gastroenterology, Vol. 101, Núm. 5, pp. 1104-1111

  2. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer

    Gut, Vol. 55, Núm. 6, pp. 848-855